StreetInsider.com News Articles

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Pizzie Nick

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084138.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Pizzie Nick

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084138.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084139.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084139.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Maizel Ari

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084140.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Maizel Ari

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084140.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: TABUTEAU HERRIOT

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084141.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: TABUTEAU HERRIOT

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084141.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Murdock Hunter R.

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084142.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Murdock Hunter R.

Fri, 27 Feb 2026 19:10:00 -0500

si-local-file:///var/storage/secattach/20260227/26084142.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Coleman Mark

Fri, 27 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260227/26084124.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Coleman Mark

Fri, 27 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260227/26084124.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Fri, 27 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260227/26084126.html

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Fri, 27 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260227/26084126.html

Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.

Thu, 26 Feb 2026 16:53:00 -0500

si-local-file:///var/storage/secattach/20260226/26072462.html

Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.

Thu, 26 Feb 2026 16:53:00 -0500

si-local-file:///var/storage/secattach/20260226/26072462.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Thu, 26 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260226/26071610.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Thu, 26 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260226/26071610.html

Form 4 Axsome Therapeutics, For: Feb 23 Filed by: Coleman Mark

Wed, 25 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260225/26062119.html

Form 4 Axsome Therapeutics, For: Feb 23 Filed by: Coleman Mark

Wed, 25 Feb 2026 19:00:00 -0500

si-local-file:///var/storage/secattach/20260225/26062119.html

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Wed, 25 Feb 2026 07:00:00 -0500

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:

TD Cowen 46th Annual Health Care Conference
Fireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA

Leerink Partners Global Healthcare Conference
Fireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL

The Citizens Life Sciences Conference
Axsome Therapeutics to Participate in Upcoming Investor Conferences

Wed, 25 Feb 2026 07:00:00 -0500

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference
  Fireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA
- Leerink Partners Global Healthcare Conference
  Fireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL
- The Citizens Life Sciences Conference
  
  Axsome Therapeutics (AXSM) PT Raised to $251 at UBS
  
  Tue, 24 Feb 2026 10:32:33 -0500
  (Updated - February 24, 2026 10:32 AM EST)
  UBS analyst Ashwani Verma raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $251.00 (from $248.00) while maintaining a Buy rating.
  The analyst commented, "AXSM stock was down 5% on 4Q25 print, due to investor concerns around elevated spend on expanded sales force. However, we note that ~300 additional reps would typically attribute ~$90m in fully-loaded FTE cost; thus there is still significant operating leverage in the P&L despite a large Commercial expansion. Also, we highlight that every sales force expansion has driven substantial Auvelity volume growth in the past (Figure 2Figure 2: Inflection
  
  Axsome Therapeutics (AXSM) PT Raised to $251 at UBS
  
  Tue, 24 Feb 2026 10:32:33 -0500
  (Updated - February 24, 2026 10:32 AM EST)
  UBS analyst Ashwani Verma raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $251.00 (from $248.00) while maintaining a Buy rating.
  The analyst commented, "AXSM stock was down 5% on 4Q25 print, due to investor concerns around elevated spend on expanded sales force. However, we note that ~300 additional reps would typically attribute ~$90m in fully-loaded FTE cost; thus there is still significant operating leverage in the P&L despite a large Commercial expansion. Also, we highlight that every sales force expansion has driven substantial Auvelity volume growth in the past (Figure 2Figure 2: Inflection
  
  Wolfe Research Starts Axsome Therapeutics (AXSM) at Outperform
  
  Tue, 24 Feb 2026 09:04:45 -0500
  (Updated - February 24, 2026 9:04 AM EST)
  Wolfe Research analyst Rudy Li initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Outperform rating and a price target of $230.00.
  The analyst comments "Lead asset Auvelity is a rapid-acting oral NMDA receptor antagonist and sigma-1 receptor agonist approved in US for MDD ➢ ~$507M sales for MDD in 2025 (>73% YoY) ➢ Approved in 2022, LOE expected in 2039 ➢ Focus on key label expansion opportunity of Auvelity in ADA ➢ BTD in June 2020; PDUFA date of April 30, 2026 ➢ 2nd asset Sunosi is approved for excessive daytime sleepiness in

StreetInsider.com News Articles

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Pizzie Nick

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Pizzie Nick

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Maizel Ari

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Maizel Ari

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: TABUTEAU HERRIOT

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: TABUTEAU HERRIOT

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Murdock Hunter R.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Murdock Hunter R.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Coleman Mark

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Coleman Mark

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.

Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Form 4 Axsome Therapeutics, For: Feb 23 Filed by: Coleman Mark

Form 4 Axsome Therapeutics, For: Feb 23 Filed by: Coleman Mark

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics (AXSM) PT Raised to $251 at UBS

Axsome Therapeutics (AXSM) PT Raised to $251 at UBS

Wolfe Research Starts Axsome Therapeutics (AXSM) at Outperform